Utama › Leukemia Mieloid Akut › Connecticut › Bridgeport
Kajian klinikal Leukemia Mieloid Akut di Bridgeport, CT
12 kajian untuk Leukemia Mieloid Akut sedang mencari peserta di lokasi dalam dan sekitar Bridgeport (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.
Teks kajian rasmi (Bahasa Inggeris)
Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Mengambil pesertaKajian pemerhatianSukarelawan sihat dialu-alukan
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Mengambil pesertaFasa 2
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Mengambil pesertaFasa 2
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Mengambil pesertaFasa 3
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Mengambil pesertaFasa 1/2
- Stony Brook University Medical Center, Stony Brook · 18 mi jauh
Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)
Mengambil pesertaKajian pemerhatian
- Stony Brook Cancer Center, Stony Brook · 18 mi jauh
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Mengambil pesertaFasa 1
- Stony Brook Cancer Center, Stony Brook · 18 mi jauh
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Mengambil pesertaKajian pemerhatian
- Stony Brook University Hospital, Stony Brook · 18 mi jauh
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Mengambil pesertaFasa 1
- Stony Brook University Hospital, Stony Brook · 18 mi jauh
Kajian Leukemia Mieloid Akut di bandar lain
- Houston, TX85 kajian
- New York City, NY51 kajian
- Boston, MA44 kajian
- Baldwin Park, CA40 kajian
- Seattle, WA40 kajian
- Columbus, OH35 kajian
- Philadelphia, PA34 kajian
- Durham, NC33 kajian
- Atlanta, GA30 kajian
- Tampa, FL29 kajian
- Chicago, IL26 kajian
- Portland, OR25 kajian
Kajian lain di Bridgeport
- Kanser Payudara21 kajian
- Kanser Paru-paru Bukan Sel Kecil14 kajian
- Kanser Paru-paru13 kajian
- Penyakit Kardiovaskular9 kajian
- Karsinoma Sel Skuamosa Kepala dan Leher8 kajian
- Kanser (semua jenis)8 kajian
- Kanser Metastatik7 kajian
- Kegagalan Jantung7 kajian
- Aneurisma Otak6 kajian
- Kanser Prostat6 kajian
- Mieloma Pelbagai6 kajian
- Kanser Darah5 kajian
Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.